Hamilton Thorne Ltd.
HTL
Classement en actions
#16944
Hamilton Thorne Ltd. is a leading enterprise focused on the development,... Hamilton Thorne Ltd. is a leading enterprise focused on the development, manufacturing, and global distribution of specialized instrumentation, laboratory equipment, consumables, software, and a range of services. The company's offerings are primarily directed towards the fields of assisted reproductive technologies (ART), scientific research, and cell biology. Their product line includes sophisticated laser and imaging systems designed for biological studies, custom-built workstations, incubators, and essential equipment for IVF laboratories. They also produce critical medical devices for reproductive medicine, such as ovum pickup needles and catheters, and provide comprehensive in-vitro diagnostic (IVD) systems, from initial research and design to sales, installation, and ongoing servicing. Environmental control solutions like the Cell-Tek Microscope Chamber, which meticulously manages temperature, airflow, and humidity, are also part of their extensive catalog, alongside laminar flow workstations. Furthermore, Hamilton Thorne pioneers software innovations, including AI-powered CASA (Computer-Assisted Sperm Analysis) for image analysis. The company's service array covers thorough laboratory testing, notably endotoxin analysis and specialized sperm assays (like the Sperm Motility Index and Sperm Penetration), as well as the provision of fresh and cryopreserved mouse embryos, coupled with technician training and proficiency testing programs. Marketed under respected brand names such as Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, MICROPTIC, Gynétics, and Embryotech, their products and services reach a diverse global customer base—including fertility clinics, hospitals, pharmaceutical and biotechnology companies, academic institutions, and various commercial research entities—via a direct sales presence in countries like the United States, Germany, France, Australia, Denmark, Belgium, Spain, and the United Kingdom, complemented by an extensive distributor network covering around 100 nations. Hamilton Thorne Ltd. maintains its headquarters in Beverly, Massachusetts.
Prix de l'action
$1.64
Dernière synchronisation: 2024-12-02
Capitalisation boursière
$253.46M
Changement (1 jour)
2.87%
Changement (1 an)
3.40%
Pays
US
Échange Hamilton Thorne Ltd. (HTL)
Catégorie
Healthcare
Ratio P/E pour Hamilton Thorne Ltd. (HTL)
Ratio P/E au October 2026 TTM : -387.83
Selon les derniers rapports financiers et le cours de l'action de Hamilton Thorne Ltd., le ratio P/E actuel (TTM) est de -387.83. À la fin de l’année 2022, le P/E de l’entreprise était de 91.33.
Historique du ratio P/E pour Hamilton Thorne Ltd. de 2008 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | -387.83 | 59.24% |
| 2023 | -243.55 | -366.69% |
| 2022 | 91.33 | -4.30% |
| 2021 | 95.43 | -39.39% |
| 2020 | 157.45 | 26.56% |
| 2019 | 124.41 | 371.95% |
| 2018 | 26.36 | 161.23% |
| 2017 | 10.09 | -72.34% |
| 2016 | 36.48 | 279.55% |
| 2015 | 9.61 | -56.10% |
| 2014 | 21.90 | 14.40% |
| 2013 | 19.14 | -996.31% |
| 2012 | -2.14 | 72.31% |
| 2011 | -1.24 | 28.28% |
| 2010 | -0.97 | 40.85% |
| 2009 | -0.69 | 565.28% |
| 2008 | -0.10 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 47.48 | -112.24% |
US
|
|
| 27.43 | -107.07% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -114.67% |
US
|
|
| - | - |
CH
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.